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Nature reviews | Endocrinology
An adequate adrenal stress response is essential to maintain 
the vital functions of the human body in health and disease1. 
However, iatrogenic suppression of the hypothalamic– 
pituitary–adrenal (HPA) axis is an increasing challenge 
for clinicians2. One important factor is the widespread 
use of novel steroid medications to manage chronic 
diseases in an ageing society1,3. Novel drugs targeting 
common disorders (for example, hypertension or cancer) 
interfere with adrenal steroid synthesis or metabolism and 
have the potential to induce adrenal suppression. Here, we 
comment on evidence and mechanisms related to medi­
cations that induce adrenal insufficiency. Furthermore, 
we suggest steps to be taken to tackle this problem.
Steroid hormone synthesis inhibitors
Common malignancies, such as prostate or breast 
cancer, are treated with hormonal deprivation therapy. 
However, in tumours refractory to the standard treat­
ments, novel selective steroid hormone synthesis inhibi­
tors show promise. For example, 17α­ hydroxylase 
(CYP17A1) inhibitors (abiraterone for prostate cancer) 
can suppress androgen production but also induce cor­
tisol deficiency4. Patients treated with these inhibitors 
require glucocorticoid replacement therapy to avoid 
adrenal crisis, to lower progesterone and aldosterone 
accumulation and to decrease hypertension. However, 
such replacement therapy (up to 10–20 mg prednisone) 
exposes patients to excess glucocorticoids and the risk of 
acute adrenal crisis4.
In the future, more potent inhibitors of androgen 
production might be developed. For example, in 2018, a 
phase I clinical trial was commenced to investigate novel 
selective cholesterol side­ chain cleavage inhibitors for 
prostate cancer5. However, this drug will induce a com­
plete blockade of the production of all major steroids, 
including cortisol, aldosterone and androgens. All treated 
patients will require hormone replacement therapy and 
should be trained in prevention of adrenal crisis.
Aldosterone synthase (CYP11B2) inhibition has the 
pot ential to prevent metabolic, cardiac and renal dysfunc­
tion in patients with the metabolic syndrome6. However, 
at higher doses, these compounds induce a general inhibi­
tion of 11β­ hydroxylase activity, which lowers aldosterone 
and cortisol production. Once these medications enter 
widespread clinical use, adrenal function, particularly 
during stress, should be monitored (Box 1).
Checkpoint inhibitors
Many patients with advanced skin tumours and other 
solid tumours as well as haematological malignancies 
are now being treated with immune checkpoint inhibi­
tors (ICIs; antibodies that block key immune check­
point proteins, such as CTLA4 or PD1). However, it has 
become apparent that ICI­ induced endocrinopathies 
are a frequent adverse effect of these medications. Over 
50% of these endocrinopathies involve an impairment 
of HPA axis function7 (Box 1). Of note, appropriate 
immune–endocrine crosstalk is crucial for the function 
of the adrenal stress axis1. For example, inflammatory 
cytokines (such as IL­1, IL­6 and TNF) regulate the 
HPA axis. Immune cells interact directly with corti­
cotrophs as well as adrenal cells. In addition, adrenal 
cells express Toll­ like receptors and chemokine recep­
tors that facilitate the immune–adrenal response during 
inflammation1.
Inflammation, sepsis and autoimmune disease are 
known to induce adrenal insufficiency1. Unsurprisingly, 
ICIs can also have a major effect on HPA axis function. 
The HPA axis might also be disrupted by inflammation 
of the pituitary gland, which blunts adrenocorticotropic 
hormone (ACTH) release, or, less commonly, ICIs might 
directly impair the adrenal gland1,7. The mechanisms of 
HPA axis dysregulation are not fully explored. However, 
data suggest that blocking expression of CTLA4 on endo­
crine cells (for example, by ipilimumab treatment) leads 
to site­ specific deposition of complement components, 
pituitary infiltration and hypophysitis7.
Alarmingly, an increase has occurred in the num­
ber of reports of adrenal crisis in patients treated with 
ICIs1,7. The first onset of symptoms can occur as early 
as 1 week or as late as 416 weeks after treatment with 
ICIs, requiring constant clinical vigilance. Furthermore, 
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the drug’s adverse effect profile might change during its 
life cycle and patients might have additional predispos­
ing factors that increase the risk of adrenal crisis. Finally, 
ICIs might affect other endocrine organs, such as the thy­
roid gland7. If hypothyroidism is treated before steroid 
replacement, then severe adrenal crisis might occur.
Multiple drug interactions
Novel medications that might have a low or moderate 
risk of inducing full adrenal insufficiency in patients 
with an intact HPA axis have the risk of causing substan­
tial damage in patients with a partially or subclinically 
impaired adrenal stress response. For example, in our 
ageing society, it is reported that >5% of the population 
have been exposed to glucocorticoid treatment and will 
have suppressed HPA axis function1.
The most common cause of HPA axis failure is sys­
temic glucocorticoid administration. For example, data 
confirm a clear dose dependency of iatrogenic gluco­
corticoid excess and adrenal insufficiency3. By con­
trast, co­ prescribing of low dose steroids (for example, 
inhaled fluticasone) together with medications inhibi­
ting CYP3A4 (for example, ritonavir) substantially 
potentiates exposure to steroids and might induce long­ 
term secondary adrenal insufficiency. Drugs that lower 
cholesterol (the substrate for steroid biosynthesis) levels 
(for example, statins or the potent PCSK9 inhibitors) do 
not affect adrenal steroidogenesis under normal condi­
tions. However, they might contribute to adrenal insuf­
ficiency under stress or in combination with other drugs 
that affect steroid metabolism8.
Patients with hepatitis or liver disease have impaired 
adrenal function. For example, a substantial proportion 
of patients with alcoholic liver disease have impaired 
adrenal function, as do patients with chronic infections 
(for example, viral hepatitis, HIV or Mycobacterium 
tuberculosis)1. In addition, up to 30% of patients receiv­
ing opioids have a suppressed HPA axis9. Opioids exert 
a tonic inhibition on the HPA axis, blocking hypo­
thalamic corticotropin­ releasing hormone (CRH) 
release and subsequent ACTH and cortisol produc­
tion. Finally, we are beginning to learn more about 
environmental endocrine disruptors and chemicals that 
block adrenal steroid production and predispose to an 
impaired HPA axis10 (Box 1).
What needs to be done?
First, we should raise awareness about this problem 
among the endocrine community and among health­ 
care professionals. Second, patients on these medications 
(Box 1) should be equipped with an emergency identifi­
cation card and a kit for self­ treatment of adrenal insuf­
ficiency. Education and training of patients, their carers 
and relatives (as required for patients with Addison 
disease) should be offered. Third, we should develop 
appropriate test systems to explore the effects of novel 
medications on HPA axis function. Finally, we suggest 
the development of a digital application using a machine 
learning algorithm to help health­ care professionals 
assess risk for adrenal insufficiency in their patients.
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Box 1 | Examples of medications causing or predisposing to adrenal insufficiency
Steroids (systemic, intra- articular or inhaled)
•	Cause	adrenal	suppression	through	negative	feedback	on	hypothalamus	and	pituitary
cyP3A4 inhibitors (HiV drugs (for example, ritonavir), antifungal drugs  
(for example, fluconazole) and antidepressants (for example, fluvoxamine)
•	Adrenal	suppression	occurs	in	combination	with	low	dose	steroids	(intranasal		
or	inhaled,	for	example,	fluticasone)
•	Potentiating	exposure	to	steroids,	which	enhances	adrenal	suppression	through	
negative	feedback
opioids (morphine, fentanyl, tramadol, methadone or mixed opioids)
•	Tonic	inhibition	on	the	hypothalamic–pituitary–adrenal	(HPA)	axis	blocking	
hypothalamic	corticotropin-	releasing	hormone	(CRH)	release
immune checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab  
and avelumab)
•	Hypophysitis	due	to	pituitary	infiltration	of	lymphocytes,	leading	to	adrenocorticotropic	
hormone	(ACTH)	deficiency
•	Less	commonly,	direct	impairment	of	adrenal	cortex
lipid- lowering therapies (statins, PcSK9 inhibitors and ldl apheresis)
•	Under	normal	conditions	may	be	safe	in	humans
•	Based	on	data	in	animal	models	and	in	state	of	very	low	cholesterol	availability		
or	impaired	liver	function,	adequate	synthesis	of	cortisol	may	be	impaired
Anti- prostate cancer drugs (abiraterone or novel steroid blocking agents,  
for example odM-208)
•	Inhibition	of	steroid	synthesis	at	multiple	levels	(for	example	cholesterol	side-	chain	
cleavage	enzyme,	17-hydroxylase	and	21-hydroxylase)	will	induce	various	degrees		
of	decreased	cortisol	production
Aldosterone synthase inhibitors (for example, lci699)
•	Inhibition	of	11-hydroxylase	activity	(CYP11B2)	at	higher	doses	will	decrease	both	
aldosterone	and	cortisol	synthesis
